Adjunctive satralizumab reduces relapse in some patients with NMOSD

• Posted on: Dec 18 2019
• By: Saratoga Opthalmology
• Leave a response

In this phase 3 trial, investigators evaluated the efficacy and safety of satralizumab as adjunct therapy for patients with neuromyelitis optica spectrum disorder (NMOSD).
Source: AAO

Posted in: Uncategorized